Kinimmune publishes results from a Phase I “Window of Opportunity” trial in patients with solid tumors
Retrieved on:
Friday, March 3, 2023
Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results from a Phase I trial in solid tumor patients.
Key Points:
- Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results from a Phase I trial in solid tumor patients.
- The paper, titled “A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors,” was published in Translational Medicine Communications.
- This work was conducted in collaboration with researchers at the University of Kansas Cancer Center and King Abdulaziz University.
- In this open label study, 9 patients with resectable solid malignancies were treated with Copaxone®, the longest approved glatiramer acetate product.